Patients with severe asthma benefit from omalizumabThe monoclonal antibody omalizumab reduces the risk of exacerbations by about 25% over the course of a year among patients with more severe, persistent asthma. How to stop worrying and love artificial sweetenersMany believe that because they are unnatural they must be unsafe, yet research shows they are safe—especially at real-world levels A stimulating experience Infectious disease centre funding renewed New biopsy key in guiding treatment of metastatic cancer Marvelling over ancient guide for medicinal plants Linking records and lab data improves diabetes outcomes: report Begin brain exercises early to slow mental decline CMA ‘transformation’ blueprint a tough read By the time its many reforms achieve consensus among key health players, it may be time for many new ones Bisphosphonates unlikely to cause esophageal cancer First Previous 382 383 384 385 386 Next Last
